Navigation Links
China Medicine Announces Conference Call to Discuss First Quarter 2008 Results
Date:5/9/2008

" target="_new">http://www.chinamedicinecorp.com .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business, products and financial results. The Company's actual results may differ materially from those anticipated in the forward-looking statements depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, and various other factors beyond the Company's control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

For more information, please contact:

Company Contact:

Ms. Huizhen Yu

Chief Financial Officer

China Medicine Corporation

Tel: +86-20-8739-1718

Email: konzern08@163.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY Office)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgelite.com


'/>"/>
SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
2. The American Psychiatric Associations Awards for Young Scientists Encourage Research Expertise in China
3. Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May
4. China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits
5. Chindex International, Inc. to Present at China Investment Conferences in New York City - May 20, 21, 22; Conferences Presented By Brean Murray, Carret & Co., Oppenhiemer & Co. and Citigroup
6. Increase in Travel to China Creating New Health and Security Risks
7. China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers
8. China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention
9. Huifeng Bio-Pharmaceutical (HFGB) Announces Participation in the 59th PHARMCHINA Expo
10. MM2 Group Provides Additional Quotes for New Venture in China
11. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2008)...ousands across the Country on Hand for Unveiling o...t Breast Cancer Organization, CHICAGO, May 11 /PR...,Day in 15 cities across the country were present ...nation,s oldest non-profit breast cancer,organizat...ization(TM) commemorates,its 30th anniversary. In ...
(Date:5/10/2008)... MINNEAPOLIS, May 10 /PRNewswire/ -- The American ...ies to the survivors of the tragedy in,Myanmar. In...ife-saving,medical supplies and food, including it... and mosquito nets to thousands of survivors., AR...week, pending,visas. The team will be led by ARC T...
(Date:5/9/2008)...nfirms popular whole grain may provide protection ... certain cancers, ARLINGTON, Va., May 8 /PRNewswi... joins the recognized ranks of healthful whole gra...he U.S. Food and Drug Administration,(FDA) that wi...grain health,claim. This will enable consumers to ...
(Date:5/9/2008)... LOS ANGELES, May 9 /PRNewswire/ -- Los Angeles ba...oned in Asia to assess the needs of what is now,an... cyclone which,destroyed or devastated wide swaths...gon (formerly the capital Rangoon) and throughout ... winds of over 120 miles per hour and,struck commu...
Breaking Medicine News(10 mins):Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:FDA Approves Health Claim for Brown Rice 2Health News:FDA Approves Health Claim for Brown Rice 3Health News:FDA Approves Health Claim for Brown Rice 4Health News:FDA Approves Health Claim for Brown Rice 5Health News:Los Angeles Based Operation USA Appeals for Funds to Aid in Myanmar (Burmese) Cyclone Disaster (Updated) 2
...in your food?' Somebody put it there for you." Bei...for high blood pressure, but too much salt plays a...sion are advised to eat a low-sodium diet, about 1... specialists are pressuring food manufacturers and...
...f the people living with chronic fatigue are undia...in, insomnia and impaired memory. It's a difficult... the 1.3 million Americans who suffer from chronic... commonly used in cancer patients may help them ge...
...announced the initial results of the three-year tr...the vaccine if it were 30 percent effective, but t...of volunteers, including all racial groups, was 3.... study, said the study "did not show a statistical...
... they all sound simple, but can they really impact...factors can significantly improve life expectancy ... centers combined efforts to determine the potenti... disease. They looked at 20 risk factors. Some of ...
Other Medicine News:Health News:Scientists push to lower hidden sodium in food 2Health News:AIDS vaccine falls short but shows some promise 2
(Date:5/8/2008)...Annual Meeting of the American Pain Society ... 8 /- Patients treated with lacosamid... neuropathic pain (DNP),compared to placebo-treat...th annual meeting of the American Pain Society (AP...trolled trial of a diabetic neuropathic,pain treat...
(Date:5/8/2008)...Newswire-FirstCall/ -- AstraZeneca (NYSE:,AZN) tod...Drug Application,(sNDA) to the U.S. Food and Drug ...ne fumarate) Extended-Release Tablets to seek appr...rder (GAD), including maintenance of,antianxiety e...ht for an,atypical antipsychotic medicine in GAD. ...
(Date:5/7/2008)...e Efficacy and Safety in Treating a Leading ...N, Germany, MONTVILLE, New Jersey and TARRYTOWN, N...lthCare AG and Regeneron,Pharmaceuticals, Inc. (NA...nt,has been dosed in the VIEW 2 trial, a second Ph...uating VEGF Trap-Eye for the treatment of the,neov...
(Date:5/7/2008)...re-FirstCall/ -- Shire plc (LSE: SHP,Nasdaq: SHPG..., today,announced findings from a new data analysi...ces with DAYTRANA(TM) (methylphenidate transdermal... with Attention Deficit,Hyperactivity Disorder (AD...t DAYTRANA has an established safety profile and e...
Breaking Medicine Technology:New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 2Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 3Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 4Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 5Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Pharsight to Host European Software Conference 1952 1Pharsight to Host European Software Conference 1952 2Health Organizations Join Forces Around Quit Smoking Help 1947 1Health Organizations Join Forces Around Quit Smoking Help 1947 2People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 1People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 2People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 3People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 1944 4GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 1GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 2GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology 1940 3
...--Mar 26, 2007 - Pfizer announced today,that Lipit...d a,significant 61 percent reduction in stroke in ...me but without heart disease. In a,separate study,...ini-stroke during the trial had a significant 53 p...nts (death from cardiac causes,heart attack, or r...
... with statins for only five weeks at,400 mg/week l...tatins alone, with similarly favorable effects on ..., Calif., March 26, 2007,/PRNewswire-FirstCall/ --...from its Phase 2 clinical trial of ISIS 301012,coa... Cardiology,Annual Scientific Session (ACC) in New...
Other Medicine Technology:Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 2Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 3Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 4Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
These unique Acid Fast Control Slides simulate a clinical sputum smear with appropriate background material. Slides have two wells containing a positive and negative smear. Can be used with Kinyoun (
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques.
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques.
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population.
Medicine Products: